Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Ad

Indication
GVHD - Graft-Versus-Host Disease

Other upcoming events for MESO

Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Ad
Phase 3 ReadoutPhase 3 Topline: A Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Ad — MESO Phase 3 Readout | BioSniper